MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:36Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Alpha-1 blockers]]
			[[Category:BPH treatments]]
			[[Category:Antihypertensives]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #180

2026-05-23T03:56:08Z

parser-claude batch MedTemplate pre-fill, Top 300 #180

New page

{{MedTemplate
| generic = Doxazosin
| brand = Cardura, Cardura XL
| structure =
| classes = [[:Category:Alpha-1_blockers|Alpha-1 adrenergic blocker (non-selective)]], [[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]], [[:Category:Antihypertensives|Antihypertensive]]
| uses = <vote slug="bph-luts-use">Benign prostatic hyperplasia (LUTS)</vote>, <vote slug="hypertension-fourth-line-use">Hypertension (later-line; first-dose hypotension limits as monotherapy)</vote>, <vote slug="nightmares-ptsd-use">PTSD-related nightmares (off-label, mostly prazosin in practice)</vote>
| starting_dose = IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily
| preparations = 1, 2, 4, 8 mg IR tablets; 4, 8 mg XL tablets
| fda_max = 16 mg/d (IR); 8 mg/d (XL)
| pill_id =
| routes = Oral
| onset = BP and symptomatic LUTS improvement within 1-2 weeks
| duration = 24 hours
| halflife = ~22 hours<ref name="cardura-label">FDA Prescribing Information, Cardura (doxazosin mesylate), Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019668s032lbl.pdf</ref>
| bioavailability = ~65% (oral)<ref name="cardura-label" />
| pregnancy = Limited data; rarely indicated in pregnancy.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="doxazosin-mech-claim">Doxazosin is a non-selective α1 adrenergic receptor antagonist that relaxes vascular smooth muscle (lowering BP) and prostatic/bladder-neck smooth muscle (improving urodynamic flow); unlike tamsulosin, it lacks α1A subtype selectivity, producing more peripheral hypotension and the characteristic '''first-dose syncope''' that drives bedtime initiation.</vote> ALLHAT (2000) showed the doxazosin arm had significantly more heart failure than chlorthalidone, leading to the general practice of using α1 blockers as later-line antihypertensives rather than first-line<ref name="cardura-label" />. Intraoperative floppy iris syndrome is a recognized class effect.
}}

== References ==
<references />

Doxazosin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #180